Evidence map›Paper›PMID 32640639›Full record

ArticleNutrients2020

Structure and Function of Bovine Whey Derived Oligosaccharides Showing Synbiotic Epithelial Barrier Protective Properties.

Peter I Duncan, Olli Aitio, Annamari Heiskanen, Ritva Niemelä, Juhani Saarinen, Jari Helin, Nadine Porta, Muriel Fiaux, Denis Moënnoz, Mireille Golliard and 4 more

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Peter I DuncanNestlé Institute of Health Sciences, Société des Produits Nestlé S.A., 1000-Lausanne 26, Switzerland.
Olli AitioGlykos Finland Ltd., 00790 -Helsinki, Finland.
Annamari HeiskanenGlykos Finland Ltd., 00790 -Helsinki, Finland.
Ritva NiemeläGlykos Finland Ltd., 00790 -Helsinki, Finland.
Juhani SaarinenGlykos Finland Ltd., 00790 -Helsinki, Finland.
Jari HelinGlykos Finland Ltd., 00790 -Helsinki, Finland.
Nadine PortaNestlé Institute of Health Sciences, Société des Produits Nestlé S.A., 1000-Lausanne 26, Switzerland.
Muriel FiauxNestlé Institute of Health Sciences, Société des Produits Nestlé S.A., 1000-Lausanne 26, Switzerland.
Denis MoënnozNestlé Institute of Health Sciences, Société des Produits Nestlé S.A., 1000-Lausanne 26, Switzerland.
Mireille GolliardNestlé Institute of Health Sciences, Société des Produits Nestlé S.A., 1000-Lausanne 26, Switzerland.
Christine CherbutNestlé Institute of Health Sciences, Société des Produits Nestlé S.A., 1000-Lausanne 26, Switzerland.
Rafael BerrocalNestlé Product Technology Center, Société des Produits Nestlé S.A., 3510- Konolfingen, Switzerland.
Sean AustinNestlé Institute of Food Safety and Analytical Sciences, Société des Produits Nestlé S.A., 1000-Lausanne 26, Switzerland.ORCID 0000-0003-0494-2858
Norbert SprengerNestlé Institute of Health Sciences, Société des Produits Nestlé S.A., 1000-Lausanne 26, Switzerland.ORCID 0000-0003-4880-2750
Nestlé (Switzerland) · CHGlykos (Finland) · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Commensal gut microbiota and probiotics have numerous effects on the host's metabolic and protective systems, which occur primarily through the intestinal epithelial cell interface. Prebiotics, like galacto-oligosaccharides (GOS) are widely used to modulate their function and abundance. However, important structure-function relations may exist, requiring a detailed structural characterization. Here, we detailed the structural characterization of bovine whey derived oligosaccharide preparations enriched with GOS or not, dubbed GOS-enriched milk oligosaccharides (GMOS) or MOS, respectively. We explore GMOS's and MOS's potential to improve intestinal epithelial barrier function, assessed in a model based on barrier disruptive effects of the

Indexed as

Gastrointestinal MicrobiomeIntestinal MucosaOligosaccharidesSynbioticsWheyAnimalsBacterial ToxinsCattleCell Line, TumorEnterotoxinsGalactoseHumansLactobacillusPrebioticsProbioticsProtective AgentsBacterial ToxinsEnterotoxinsGalactoseOligosaccharidesPrebioticsProtective AgentstcdA protein, Clostridium difficileepithelial barrier functionhost–microbiota interactionlactobacillus probiotic

Identifiers

PMID32640639
PMCPMC7400958
OpenAlexW3039796481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.